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Abstract 
PROTEOMIC ANALYSIS OF MORINGA OLEIFERA’S ANTI-ARTHRITIC EFFECTS ON 
HUMAN FIBROBLAST-LIKE SYNOVIOCYTES 
Brianna Nicole Tate 
B.A., Appalachian State University 
Chairperson:  Chishimba Nathan Mowa, Ph.D. 
Rheumatoid arthritis (RA) affects more than 1.3 million Americans, making it the most 
common auto-immune arthritic disorder in the U.S. Current treatments are largely based on 
non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. However, these drugs 
are either ineffective, costly or have a plethora of side effects, notably immune suppression 
and increased risks of heart attacks. Therefore, here, we sought to examine the anti-arthritic 
effects of a tropical medicinal plant, Moringa oleifera (MO), and its underlying mechanism 
using proteomics analysis and primary human fibroblast-like synoviocytes (HFLS) harvested 
from healthy people and patients with arthritis (HFLS-RA). Initial experiments optimized 
MO’s optimal dosage by examining MO’s effect on cell viability using MTT assay. Cells 
were divided into the following groups: 1) Negative control groups [a) HFLS and b) HFLS-
RA, 0.1M phosphate-buffered saline (PBS) only] and 2) MO treatment group (HFLS and 
HFLS-RA), dose-dependent treatment (500 µg/mL, 750 µg/mL, 1000µg/mL, 50 mg/mL, 75 
mg/mL, 100 mg/mL, 150 mg/mL and 200 mg/mL). For proteomics studies, cells were 
divided into the following groups: 1) Negative control group (HFLS-RA), vehicle only (as 
above) and 2) MO Treatment group (HFLS-RA), 75 mg/mL (optimal concentration). After 
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24 hours of treatment, cells were harvested and analyzed for cell viability (MTT assay) or 
proteome-wide expression (Proteomics). Data generated from proteomics were verified by 
confocal immunofluorescence. The MTT assay data shows that below 75 mg/mL, MO is not 
cytotoxic and therefore does not affect cell viability. Proteomics data revealed that MO alters 
expression of all the 40 proteins that are aberrantly expressed in HFLS-RA by either 
mitigating their expression (35 proteins) or enhancing (5 proteins) them. Specifically, the 35 
proteins were mostly associated with pathological processes, such as inflammation, aberrant 
proliferation and cell adhesion, whereas the 5 proteins (Heat shock 70 kDa protein 1A/1B, 
Kallistatin, programmed cell death 6-interacting protein, Hemoglobin subunit alpha, and 
Aldo-keto reductase family 1 member C1) were associated overall with normal protective 
processes, such as anti-inflammatory and apoptotic activities, were down regulated in HFLS-
RA. We conclude that MO is potentially a good candidate for developing alternative therapy 
for managing arthritis.
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1 
 Introduction 
Study overview 
The present study investigates the suitability of a tropical medicinal plant, Moringa oleifera 
(MO), as an alternative therapy to Rheumatoid arthritis (RA), one of the prevalent diseases in 
the US that disproportionately affect women. Current treatments are not only costly but are 
associated with multiple side effects. MO was considered for investigation because it is a 
potent modulator of inflammation and proliferation, two prominent pathogenic processes 
associated with RA. 
 
Rheumatoid arthritis 
Overview of RA  
RA is a chronic inflammatory auto-immune disease characterized by persistent 
synovitis, systemic inflammation, production of auto-antibodies and destruction of affected 
bone and cartilage, which leads to progressive damage and loss of function of the joint (Scott 
et al, 2010). While RA primarily targets the joints, the disease can result in systemic 
complications, such as rheumatoid nodules, pulmonary involvement or vasculitis, and 
systemic comorbidities (Smolen, 2016). Although RA is the most prevalent autoimmune 
disease, affecting 1% of the American adult population, its cause has remained elusive 
(Parker, 2017).  In addition, RA’s treatment is costly and its’ effectiveness is wanting. 
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Epidemiology and cost of RA  
RA is most prevalent in women and the elderly, i.e., seventy-five percent of RA 
patients are women, making them three times more susceptible than their male counterparts 
(Scott, 2010). Women also have an earlier peak onset age of arthritis, occurring in the fourth 
to fifth decades, whereas in men, the prevalence increases in the sixth to eighth decades 
(Parker, 2017). The exact reason for the heightened risk in females has not be elucidated but 
it has been hypothesized that it could be due to hormonal changes that take place in 
menopausal women as well as genetic factors pertaining to genes associated with RA that are 
located on the X chromosome (Scott, 2010).  
The costs of medications to manage the disease, such as methotrexate, are prohibitive; 
averaging approximately $5825 per annum in pharmacy-related expenditures, compared to 
$1264 for patients without arthritis (Mukherjee, 2017). Given these conditions, namely 
prohibitive costs and associated side effects, it is important that we develop alternative 
therapies that are more effective as well as affordable and safer. 
 
Pathogenesis and signaling pathway of RA 
The exact onset of RA pathogenesis is not clear but it (RA) is initiated when antigen-
presenting cells, such as dendritic cells and macrophages (and others) present auto-antigens, 
which subsequently activates auto-reactive T-cells. Auto-reactive T-cells are immune cells 
that recognize endogenous antigens within the host and, thus, attack the body’s own tissues. 
This anomaly is one of the fundamental characteristics of the early events of the disease 
(Weisman, 2011). Following these changes, the synovium, or synovial membrane, is then 
infiltrated by an influx of immune cells, including T cells, B cells and macrophages via 
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activated endothelial cells that secrete adhesion molecules (Smolen et al., 2007; Weisman, 
2011). The previously activated T cells accumulate in the joint and begin to secrete 
interleukin-2 and interferon-γ which, in turn, activates and differentiates other immune cells, 
such as macrophages and B cells, as well as cells found within the joint, such as fibroblasts 
and osteoclasts (Smolen et al., 2007; Weisman, 2011). The B cells, once activated, can either 
serve as antigen-presenting cells to the other T-cells, subsequently activating these cells (T-
cells), thus perpetuating a cycle of positive feedback among the two cell types. Alternatively, 
these cells can differentiate into plasma cells, which then produce auto-antibodies to a variety 
of target molecules, including rheumatoid factor, vimentin or fibrinogen (Smolen et al., 
2007).  These auto-antibodies can then go on to form immune complexes that result in the 
production of pro-inflammatory cytokines, such as tumor necrosis factor (TNF) via 
complement and Fc-receptor activation (Smolen et al., 2007; Weisman, 2011). The 
stimulated macrophages also produce pro-inflammatory cytokines, as well as activate 
synoviocytes in the joint, which then secrete inflammatory cytokines of their own that 
ultimately results in the breakdown of the proximate cartilage and bone (Weisman, 2011).  
The synovium 
The synovial membrane, or synovium, is a layer of tissue that encases diarthrodial 
joints (Bottini & Firestein, 2013). This layer of tissue is populated by two key cell types, 
namely macrophage-like type A synoviocytes and fibroblast-like type B synoviocytes 
(Firestein, 1996). In a patient affected by RA, the macrophage-like cells display an 
“activated” phenotype and produce pro-inflammatory cytokines, chemokines and growth 
factors. These inflammatory signals activate local fibroblast-like synoviocytes in the 
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synovium and they, in turn, produce more inflammatory mediators, namely IL-6, prostanoids, 
and matrix metalloproteinases (MMPs) (Bartok & Firestein, 2010).  
The fibroblast-like synoviocytes are the key cells in joint erosion and their activation 
and subsequent secretion of matrix-degrading enzymes and inflammatory factors that further 
enhance the inflammatory cycle in RA and systematically break down the extracellular 
matrix, ultimately resulting in damage to the bone and cartilage (Bartok & Firestein, 2010; 
Neumann et al., 2010). Further, these cells have been implicated in the hyperplasia of the 
synovium. Once activated, these cells begin to exhibit characteristics analogous to that of 
tumor cells. They form an expansive synovial tissue called ‘pannus’ at the cartilage-bone 
interface (Bartok & Firestein, 2010). This is likely due to their upregulation of oncogenes 
involved in cell cycle regulation or that act as transcription factors, such as c-fos, ras, raf, 
myc and myb. Their lack of apoptosis and their uptick in proliferation result in the synovium, 
which under physiological conditions is usually only 1-3 cells thick, to instead become 10-15 
cells thick (Bartok & Firestein, 2010; Neumann et al., 2010). The pannus is said to behave 
like a locally invasive tumor (Bartok & Firestein, 2010). This tissue cloaks the cartilage and 
erodes into bone.  
Bone Erosion 
Bone erosion is a key hallmark of RA and usually occurs in the latter stages of the 
disease (Schett & Gravallese, 2012). The cells responsible for this phenomenon are called 
osteoclasts. Osteoclasts are giant multinucleated cells of a monocyte/macrophage origin 
which populate bone surfaces throughout the body (Takayanagi et al., 2000). Their normal 
function in the body is bone reabsorption. They do so by adhering tightly to the bone surface 
via interactions with both integrins and extracellular matrix proteins, as well as by 
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assembling tight junctions. This process seals the bone surface and the osteoclast together 
and separates the bone from the surrounding extracellular space. Proton pumps located along 
the peripheral of the osteoclasts create an acidic milieu, enabling solubilization of calcium 
from bone (Schett & Gravallese, 2012).  
However, upon onset of disease, this regulated process becomes destructive. 
Synovitis which, as mentioned before, takes place due to the dysregulation of the apoptotic 
and proliferative mechanisms in the fibroblast-like synoviocytes of the joint, provides a 
source of pro-inflammatory cytokines, which, in turn, drives the process of osteoclast 
differentiation (Schett & Gravallese, 2012). The TNF, IL-1, and IL-6 secreted by the 
synoviocytes augments the osteoclastogenesis process. They do so through upregulation of 
RANK-L expression in mesenchymal cells and through direct effects on osteoclast precursor 
cells. TNFα stimulates differentiation of osteoclast precursor cells into mature osteoclasts 
and IL-1 acts on osteoclasts to increase their bone-resorbing capacity (Goldring, 2003). The 
expression of receptors for osteoclast differentiation, such as RANK-L, is also stimulated by 
cytokines derived from the synovium (Schett & Gravallese, 2012). T cells can have a similar 
effect on the differentiation of osteoclasts through their secretion of RANK-L (Firestein, 
2003). In fact, in one murine in vivo study, it was found that with adjuvant-induced arthritis 
T-cell activation lead to a RANK-L-mediated increase in osteoclasts and subsequent bone 
loss (Kong et al., 2009). Additionally, in RANK-L knockout mice there is significant 
reduction in bone erosion, even in arthritic models (Pettit et al., 2001). Once differentiated, 
osteoclasts then begin to efflux calcium from the surrounding bone, resulting in irreversible 
damage to the joint. 
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Cartilage Damage 
The cartilage remodeling process is entirely mediated by a single type of cell: the 
chondrocyte (Goldring et al., 2003). These cells are responsible for the synthesis of the 
complex extracellular matrix of the articular cartilage. They also produce proteinases and 
other mediators that degrade the damaged matrices to permit repair. Unlike bone, which can 
be, and is, continuously remodeled throughout life, cartilage turnover is limited and, once 
damaged, this tissue is restricted in its ability to repair itself (Goldring et al., 2003).   
There are many similarities between the mechanisms that result in bone erosion and 
those that play a role in cartilage degradation in RA. Both are mediated by the activity of 
synoviocytes in the synovium and the cytokines they secrete (Goldring et al., 2003). There 
are two key mechanisms by which the arthritic synovial tissues contribute to cartilage loss. 
The first is the effect that their cytokines and other mediators that they release have on the 
dysregulation of chondrocyte function. IL-1 and TNFα are two key products of synovial 
fibroblasts that function in this manner. IL-1 is said to be more potent than TNFα in respect 
to their effects. Studies have shown that IL-1 stimulates chondrocytes to produce matrix 
metalloproteinases, also known as MMPs, and other degenerative products, such as nitric 
oxide (Neumann et al, 2010). In addition to chondrocyte dysfunction and destruction of the 
extracellular matrix of the cartilage, the second mechanism by which synovial tissues cause 
cartilage degradation is through decreasing the synthesis of cartilage-specific collagens and 
proteoglycans, which would otherwise aid in the remodeling of the cartilage tissue 
(Saklatvala et al., 1986). By mediating these two pathways, the synovial tissue is directly 
responsible for the characteristic cartilage damage observed in RA patients.   
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Current treatments of RA and associated shortfall 
As prevalent and debilitating as RA is, it should come as no surprise that there is a 
wide variety of pharmaceuticals currently on the market that seek to attenuate the symptoms 
of the disease, and more are still currently being developed. The primary goal of arthritic 
treatments is to slow the disease progression, reduce pain, aid in mobility, and improve the 
overall quality of life for the patient. There are three major classes of drugs that are typically 
used to treat RA: Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal 
Anti-Inflammatory Drugs (NSAIDs), and corticosteroids (Scott et al, 2010). 
 
Non-Steroidal Anti-Inflammatory Drugs 
The NSAIDs class of drugs are used for managing the pain experienced by patients 
with RA (Scott et al, 2010). Drugs included in this category are aspirin and ibuprofen. This 
class of drug primarily works, in low doses, by inhibiting the activity of cyclooxygenases 
and, consequently, inhibits the synthesis of prostaglandins (Brooks & Day, 1991). It should 
be noted, however, that this is not the sole way in which NSAIDs attenuate inflammation. 
Certain NSAIDs have been found to inhibit various lipoxygenase enzymes in vitro and in 
vivo. The NSAIDs responsible for this do so by reducing the production of leukotrienes and 
prostaglandins from leukocytes and synovial cells by allowing for the reincorporation of free 
arachidonic acid into triglycerides, instead of allowing it to be metabolized into lipoxygenase 
enzymes, which play a role in the inflammatory process (Brooks & Day, 1991). NSAIDs, 
have also demonstrated inhibiting effects on neutrophil function, including cell-cell 
aggregation. At high doses, NSAIDs have been found to interfere with processes not 
dependent on prostaglandins, such as the activity of enzymes (i.e., phospholipase C), the 
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synthesis of proteoglycan by chondrocytes, transmembrane ion fluxes and cell-cell binding. 
These actions of NSAIDs, however, have rarely been demonstrated in humans (Brooks & 
Day, 1991). 
Disease Modifying Anti-Rheumatic Drugs 
This class of drugs, also known as DMARDs, is the most widely utilized drug to 
manage RA. There are two classes of DMARDs: biologics and non-biologics (Scott et al 
2010). Methotrexate, a non-biologic, is usually the first drug-of-choice in the management of 
arthritic symptoms, regardless of duration or severity of the disease (Scott et al, 2010). It is 
believed that methotrexate works by “starving” malignant cells for the purine and pyrimidine 
precursors of DNA and RNA. These molecules (purine and pyrimidine) are required for 
proliferation as they inhibit dihydrofolate reductase, the enzyme responsible for producing 
reduced folate, which is necessary for the synthesis of many molecules, including purines 
and pyrimidines (Cronstein, 1997). Nonetheless, the mechanisms of methotrexate, and 
DMARDs as a whole, are poorly understood. Due to its (Methotrexate) ability to reduce 
synovitis, methotrexate and leflunomide (an alternative to methotrexate) appear to have 
bone-sparing effects (Schett & Gravallese, 2012). 
 The biologic DMARDs are usually used to treat patients with moderate to severe RA 
and are typically only used if the patient does not respond well to the non-biologics 
DMARDs. They work in a multitude of ways, depending on the drug. Some are TNF 
inhibitors, others inhibit T-cell activation, and still others serve as agonists for targets such as 
IL-1 and IL-6 (Scott et al, 2010). However, as stated before, the mechanisms of action for 
DMARDs, as a whole, is still not fully understood. 
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Corticosteroids 
This class of drugs is used by about 25%-75% of arthritic patients, though its use is 
highly controversial due to its harsh side effects, including hypertension, adrenal suppression, 
increased risk of infection and GI bleeding (Scott et al, 2010). Corticosteroids work by 
preventing the formation of both prostaglandins and leukotrienes, two key players in the 
inflammatory response, by causing the release of lipocortin. This molecule inhibits the 
production of phospholipase A2 and, thus, reduces the production of arachidonic acid, 
implying that the arachidonic acid cannot be metabolized into lipoxygenase enzymes, which 
would further exacerbate the inflammatory response (Vane & Botting, 1987). 
 
Moringa Oleifera (MO): 
Overview of MO 
Historically, MO has been renowned for its many medicinal properties for hundreds of 
years (Sujatha & Patel, 2017). Aside from being consumed as a daily vegetable, MO has 
been utilized in folk medicine in order to treat a wide array of different maladies (Abdull 
Razis et al., 2014). All parts of the plant are edible and contain constituents that lend 
themselves to the versatility of the MO plant in its ability to treat multiple ailments, 
including, but not limited to, microbial infections, ulcers, diabetes and cancers (Sujatha & 
Patel, 2017; Abdull Razis et al., 2014; Arulselvan et al, 2016). As MO becomes more widely 
studied, more of its properties and mechanisms of action are being elucidated, especially 
those associated with its anti-inflammatory characteristics (Abdull Razis et al., 2014; Mittal 
et al., 2017). Through extensive research, it has been found that the MO contains compounds 
that exhibit potent anti-inflammatory effects, notably quercetin and kaempferol, which are 
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produced in high levels by the plant (Coppin et al, 2013). Due to the anti-inflammatory 
nature of the MO plant, in addition to its accessibility, low costs, and lack of known 
significant side effects, it is possible that it could be effectively utilized to treat many 
inflammation-based diseases, such as diabetes, cancer and RA, as an alternative to the current 
therapeutics on the market. However, in order to develop and commercialize phytomedicines 
for use in a clinical setting, it is important to understand the mechanisms by which MO is 
able to attenuate inflammatory and related pathways.  
Use of MO in inflammation-related disorders 
It should come as no surprise that due to the abundance of anti-inflammatory 
compounds, researchers have turned to MO to develop alternative therapies to current 
pharmaceuticals. The over-expression of pro-inflammatory cytokines has been implicated in 
a number of autoimmune disorders, such as RA, inflammatory bowel disease (IBD), 
psoriasis, systemic lupus erythematosus (SLE), and organ graft rejection (Koneni et al, 
2009). Since MO bioactive compounds have been shown to effectively downregulate the NF-
κB pathway (REF), it shows great promise in the treatment and management of certain 
autoimmune diseases, including RA.  
Indeed, studies are already utilizing MO to treat autoimmune diseases, including RA, 
and IBD. These studies show that MO is effective in attenuating the symptoms of these 
conditions (Das & Kanodia, 2012; Mahajan et al, 2007). In one study, rats induced with IBD 
were treated with the ethanolic extract of MO leaves. It was found that the MO was effective 
in protecting the gut of the rats from oxidative stress, a process thought to play a significant 
role in the pathogenesis of IBD. There was a significant increase in antioxidant parameters 
and a reduction in the markers of oxidative stress (Das & Kanodia, 2012). In another study 
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where rats were induced with experimental arthritis and treated with the ethanolic extract of 
MO seeds, a similar pattern was observed. There was a significant increase in the antioxidant 
markers, although there were no significant changes in the markers of oxidative stress. The 
extract did, however, cause a significant reduction in the swelling of the joints of the rats, as 
well as in the expression of rheumatoid factor (Mahajan et al, 2007). It has also been shown 
that the ethanolic extract of MO also has immunomodulatory effects as well. One study 
found that MO is able to suppress macrophage phagocytic activity, which in turn affects the 
role of the B-cells in a humoral immune response (Mahajan & Mehta, 2010). Humoral 
immunity is an important target in the management of certain autoimmune diseases, 
especially rheumatoid arthritis, which is caused by dysregulation in the activity of key 
immune cells (Drexler et al 2008). These in vivo studies show that MO extracts have the 
medicinal potential to mediate and manage the progression of certain autoimmune diseases. 
 
Objectives of current study 
 
Recently, an increasing number of studies have demonstrated the multiple medicinal 
properties of MO (Gilani, 2006), notably anti-inflammatory using ethanolic extract (Mahdi et 
al., 2017). In fact, the ethanolic extract was found to attenuate arthritic symptoms both in an 
in vitro and in vivo model of RA (Coppin et al, 2013, Mahdi et al., 2017). Therefore, in the 
present study, we sought to elucidate the effect and underlying mechanism of the ethanolic 
extract of MO on human fibroblast-like synoviocytes in vitro from arthritic patients using 
proteomics. The leaves of MO contain polyphenols and flavonoids which have potent anti-
inflammatory properties (Coppin et al, 2013; Sherma et al., 2014). 
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 Materials and Methods 
Cell culture and Moringa oleifera treatment 
Human Fibroblast-like synoviocytes harvested from a 47-year old Caucasian male with 
rheumatoid arthritis (HFLS-RA) were purchased from Cell Applications (San Diego, CA, 
USA). These cells were cultured in Synoviocyte growth media (Cell Applications, San 
Diego, CA, USA). Cells were seeded in 10-cm culture plates (VWR, Radnor, PA) at a 
density of 7, 000 cells/cm2, based on the manufacturer’s recommendations and previous 
studies (Sable et al., 2016). All cells were cultured for 24 hours at 37 ̊C and 5% CO2. After 
treatments (see below), cells were harvested and analyzed for cell viability using MTT assay 
and proteome-wide protein expression, which was verified by confocal immunofluorescence. 
After cells reached a high confluency (>90%), they were treated based on the analysis 
(described earlier), i.e., A) MTT assay treatment groups: divided into the following groups, 
based on their treatment: 1) Vehicle groups [a) HFLS and b) HFLS-RA, 0.1M phosphate-
buffered saline (PBS) only], which served as negative control groups and 2) dose-dependent 
treatment of MO (500 µg/mL, 750 µg/mL, 1000µg/mL, 50 mg/mL, 75 mg/mL, 100 mg/mL). 
B) Proteomics/confocal immunofluorescence treatment groups: 1) Negative control groups 
(HFLS-RA), vehicle only (0.1M PBS), 2) MO Treatment group (HFLS-RA), 75 mg/mL MO. 
Based on initial optimization experiments, passages 3-6 and MO dosage of 75 mg/dL were 
determined to be optimal and were, thereafter, used in all subsequent experiments. MO was 
grown, harvested, processed and obtained from North Carolina A & T University 
(Greensboro, NC).  
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MTT Assay 
In order to determine the optimal dosage of MO that is not toxic to cells, initial studies 
were conducted using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide 
(MTT) assay (Sigma Aldrich, St. Louis, MO). Briefly, HFLS-RA cells and non-arthritic cells 
(HFLS) were seeded in 96-well plates at a density of 3 × 104 cells/well, and were treated with 
500, 750, 1000µg/mL and 50, 75, and 100 mg/mL of ethanolic MO whole leaf extract or 
0.1M PBS only, as described earlier. After 24 and 48 h of incubation, 2.5 mg/mL of MTT 
solution was added to the wells, and the cells were then incubated for 2 h. The absorbance of 
each well was measured using a Bio-Rad 680 microplate reader (Bio-Rad laboratories, 
Hercules, CA, USA) at 570 nm. Based on MTT assay results, 75 mg/mL was determined as 
the optimal concentration and was, therefore, used in all subsequent experiments. 
 
Proteomics 
Proteomics analysis was used to delineate the proteome-wide effect of MO on arthritic 
cells, identify the signature proteins of MO’s biological effects, as well as determine its likely 
underlying mechanism on arthritic cells.  
Briefly, harvested cells were snap-frozen and stored at –80oC until processing.  The total 
protein was extracted and quantified using a BCA assay (Thermo Scientific, Waltham, MA). 
To extract protein, cells were rinsed with ice-cold PBS then lysed within the vessel with 
RIPA buffer. Then, using a cell scraper, cells were harvested and transferred to a pre-chilled 
1.5mL Eppendorf tube. The cell suspension was then incubated on ice for 10 minutes before 
being centrifuged for 10 minutes at 10,000 x g at 4℃. The supernatant was then collected 
and stored in a clean Eppendorf tube at -80℃. 
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Study Samples:  
Eight (4) whole protein samples were extracted from human Fibroblast-like-
synoviocyte cell culture lysates (normal and diseased) (n=2) using RIPA buffer (Thermo 
Scientific, Waltham, MA) based on the following treatment groups: a) Control group: UNT-
RA and b) Treatment group: (RA + Moringa [M]). The supernatant was then immediately 
stored at -80C and later transported to the core facility Laboratory of the David Murdock 
Research Institute under dry ice for proteomics analysis. 
 
Sample Preparation:  
The samples were assayed using the Thermo Scientific Micro BCA Protein Assay kit 
to determine protein concentration. The samples were diluted to fall within the linear 
working range of the kit (5-200µg/mL) and the concentrations were calculated based on 
absorbance values compared to a BSA standard curve. The samples were then filtered using a 
3kD ultra centrifugal filter to exchange the dissolution solvent with a mass spectrometry 
friendly buffer. Hundred (100) µL of sample was diluted to 500µL with 50mM ammonium 
bicarbonate and filtered. The samples were rinsed with 200µL ammonium bicarbonate and 
filtered. The tubes were inverted and centrifuged to collect the sample. The sample 
identification, the stated concentration, and 10 µg volumes are listed below in Table 1: 
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Table 1: Identification and protein concentration of each sample analyzed. 
 
 
A volume of each sample corresponding to 35µg of protein (based on the protein 
quantization results) was used. The sample volumes were made equal by adding 50mM 
ammonium bicarbonate (AmBic) to a volume of 29.8µL. A 1% solution of Rapigest was 
added to each sample to denature the proteins and the mixture was placed in a shaking heated 
mixer at 40°C for 10 minutes. Disulfide bonds were reduced by adding 200mM dithiothreitol 
(DTT) to each sample and heating the tubes to 80oC for 15 minutes. Free sulfur atoms were 
alkylated with 400mM Iodoacetamide (IA) by placing the tubes in the dark for 30 minutes at 
room temperature. A tryptic digest was performed by adding 0.7µg Gold-Mass Spectrometry 
grade Trypsin to each tube and incubating overnight at 37oC. Alcohol dehydrogenase (ADH) 
digest from yeast was added to a final concentration of 50fmol/µg protein. The trypsin 
reaction was stopped and the Rapigest was degraded with the addition of 10% TFA/20% 
acetonitrile/70% water that was then heated to 60oC for 2 hours. The samples were 
centrifuged and the supernatant pipetted into auto sampler vials.  
 
A protein standard (BSA) was performed through the reduction/alkylation and digestion 
steps and used as a QC of the sample preparation steps and instrument performance.  LC 
solvents for peptide separation included a) water containing 0.1% formic acid; and b) 
acetonitrile containing 0.1% formic acid. The study sequence consisted of the study sample 
Sample ID Protein Concentration ng/mL 10 μg of protein in μL
UNT-RA - A 429.57 23.3
UNT-RA - B 302.25 33.1
RA+MO - A 362.57 27.6
RA+MO - B 344.43 29.1
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injections bracketed by a pair of QC injections. Data from all study samples were acquired 
using Data Dependent™ scans (Nth order double play) on the LTQ Orbit rap XL. Database 
searches were performed in Elucidator (Rosetta Bio software) using MASCOT (Matrix 
Sciences, London, UK). Analytical results were also viewed in Scaffold (Proteome Software, 
Portland, OR). QC and study samples were evaluated to confirm data quality. Liquid 
chromatography total ion current (TIC) outputs were assessed for signal quality and changes 
in signal intensity. Results were also monitored for signal trends, such as a consistent 
increase or decrease in TIC maximum values, and MASCOT search results were used to 
monitor the quality of the MS data. 
 
 Confocal immunofluorescence 
Confocal immunofluorescence was employed to verify and complement proteomics data, 
as well as for cellular localization. Briefly, cells were cultivated in 35 mm glass bottom cell 
culture dishes (Cellvis, Mountain View, CA) and then fixed in the culture using a 3% 
formaldehyde/PBS solution for 15 minutes at room temperature, followed immediately by 
three washes in 0.1M PBS. The cells were then permeabilized in 0.4% Triton X / PBS 
solution for 5 minutes, washed again as previously described in 0.1M PBS. Immediately 
following the washes, 50 µL of a primary staining solution containing 5% donkey serum 
(Sigma Aldrich, St. Louis, MO) and primary antibody (Cell Signaling, Beverly, MA) in PBS 
at a dilution of 1:100 was added to each coverslip. The primary antibody used was an anti-
NF-ƙB p65. The cover slips were incubated at room temperature overnight in the dark then 
washed with PBS as described previously. The secondary staining solution containing 5% 
donkey serum and diluted at 1:600 with anti-rabbit IgG secondary antibody (Cell Signaling, 
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Beverly, MA) was added (50 µL) to the cells and incubated for 1 hour at room temperature in 
the dark followed by three washes in PBS. Ten microliters of mounting media containing 
DAPI (Thermo Scientific, Waltham, MA) was then added to the coverslip and allowed to 
mount for 24 hours. Cells were imaged within the cell dishes using the Ziess LSM 510 
microscope. Default files in the software for TRITC and DAPI were used in order to 
visualize the fluorescent probes. Images were taken using the Ziess LD Plan-Neofluar 
40x/0.6 Kor objective lens. 
 
 Statistical Analysis 
Proteomics:  
Raw mass spectrometry (MS) data files for the study samples, collected on the 
Thermo Orbit rap XL system, were processed in Elucidator. MS data were grouped in 
Elucidator based on sample group and aligned. Sample groups were used to assist in data 
alignment, feature identification, and were utilized for QC assessment and group 
comparisons. Data were processed from retention time, 8-90 min. Thermo Orbit rap data files 
were searched using the Mascot search engine against the SwissProt mouse database 
(appended with yeast ADH, March 2, 2010). The aligned mass features were annotated with 
these database search results using the results from the system Peptide Tellers and a predicted 
error rate of 1%. MS data were summarized to the feature level, normalized, and an error-
weighted ANOVA test was performed to compare the expression results between sample 
groups. Candidate differentially expressed markers were determined based on a p < 0.01. 
Features were summarized by protein based on the results of the database search. 
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Results 
MTT Assay  
MO has an inhibitory effect on the cell viability of healthy and arthritic 
synoviocytes. Initial preliminary MTT assay screening, which sought to determine the 
optimal non-toxic concentration of MO treatment for the synoviocytes, revealed that 
concentrations above 100mg/mL exhibited cytotoxic effects on the cells [Data not shown]. 
Follow up experiments showed that concentrations below 75 mg/mL preserved cell viability 
of both synoviocytes (Figure 1). 
 Proteomics  
Forty proteins were identified in the untreated arthritic cells and the Moringa-
treated arthritic cells as having their expression changed as a result of treatment. A 
total of 40 distinct proteins were identified in arthritic cells of both the untreated and MO-
treated groups (Figure 2). Out of these 40, the expression of five proteins were down 
regulated by arthritis (untreated arthritic cells) but MO reversed their expression, i.e., MO 
up-regulated the expression of these five proteins that were down regulated in untreated 
arthritic cells (Figure 2). In contrast, while the remaining 35 proteins were upregulated by 
arthritis in the untreated cellular disease model (Figure 3.), MO treatment mitigated this 
expression pattern by down regulating their expression (Figures 2, 3). 
 Moringa oleifera mitigates enhanced expression of diverse pathological 
pathways in arthritic cells. When the 27 proteins (Figure 2), with consistent enhanced 
expression in untreated arthritic cells, discussed earlier, were categorized in biological 
themes using the UniProt tools, the identified themes included: a) translation (ribosome-, 
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transport-, protein quality- and endoplasmic reticulum-associated proteins), b) cell adhesion-
associated proteins, c) inflammation-associated proteins, d) oxidative stress resistance-
associated proteins, e) Cell signaling, f) cytoskeleton-associated and g) miscellaneous (Figure 
3A).  Interestingly, when these arthritic cells were treated with MO, the enhanced expression 
of all the proteins in all the biological themes were mitigated by MO (Figures 4-9).  
Moringa oleifera reversed the diminished protein expression of anti-
inflammatory and pro-apoptotic pathways. The 5 proteins (see Figures 3B, 10) whose 
expression were diminished in arthritic cells were categorized in 3 major biological themes, 
notably apoptosis, anti-inflammation and stress resistance (Figure 3B). Treatment of these 
diseased cells with MO reversed the protein expression trend by increasing their expression 
(Figure 3B, 10).  
Confocal Immunofluorescence  
Moringa down regulates expression of NF-ƙB p65. Expression of NF-ƙB p65 
appeared to decrease in arthritic cells treated with MO compared with the control group 
(Figure 11).  This data verified proteomics data.  
20 
Discussion 
Previous in vivo studies have shown MO’s anti-arthritic effects but not its underlying 
mechanisms. Therefore, the aim of the present study was to elucidate the anti-arthritic effects 
of the ethanolic extract of MO using an in vitro arthritic model and proteomics. Cell viability 
assays determined that the optimal concentration of MO in the arthritic cells was 75 mg/mL. 
We show here that MO mitigates the effects of arthritis by reversing the enhanced expression 
of proteins associated with a number of aberrant pathways, notably those associated with 
inflammation and proliferation. Also, we show that MO enhances expression of another set 
of biological themes, which were weakly expressed in arthritic cells, notably apoptotic and 
anti-inflammatory proteins. 
Arthritis is characterized by various aberrant pathways, notably pronounced 
inflammation (Weisman, 2011). The present data is consistent with earlier findings and 
specifically revealed increased expression of two inflammatory-related proteins, namely 
NEDD8 and Leucine-rich pentatricopeptide repeat cassette (LPPRC), whose expression were 
mitigated by MO. NEDD8 is a mammalian member of the ubiquitin-like (UBL) family of 
proteins and it covalently ligates to target proteins through “neddylation” (Takashima et al, 
2012; Amir et al, 2004), which triggers changes within the target protein, subsequently 
initiating other pathways. For example, NEDD8 is known to target cullin/Cdc53 family 
proteins leading to formation of an E2-E3 complex and subsequently increased activity of 
Skp, Cullin, F-box containing (SCF) complexes (Amir et al., 2004), which ubiquitylates 
phosphorylated IƙBα ultimately transporting NF-ƙB, the master transcription of 
inflammation, to the nucleus for initiation of inflammation (Kawakami et al., 2001). NEDD8 
is also known to block the function of tumor suppressor p53, which is involved in the 
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regulation of proliferation and apoptosis, via proteasomal degradation.  This inactivation (via 
NEDD8) causes cells, such as the fibroblast-like synoviocytes, to lose their proliferative 
activity (Keisuke et al, 2001; Yang et al, 2005). 
 Leucine-rich PPR motif-containing protein (LPPRC) is known to exert multiple 
roles, including those involving mitochondrial activity and the expression and stability of the 
COX subunits, namely CO1 and CO3, which are essential for the formation of cytochrome c 
oxidase (Xu et al, 2004). Further, LPPRC expression is also significantly upregulated in 
hepatocellular carcinoma cell lines and when LPPRC was knocked down in vitro, their 
tumorigenic activity, such as colony formation and invasive abilities, was significantly 
diminished (Michaud et al, 2011). Lastly, LRPPRC prevents apoptosis via enhancing 
expression of pro-survival Bcl-2 family members, such as Bcl-2, BclxL and Mcl-1. 
Collectively, these data highlight the role of LPPRC in proliferation and MO likely inhibits 
the aberrant cellular proliferation and inflammation in arthritic cells, in part, by down 
regulating the expression of LPPRC and NEDD8. 
D-dopachrome decarboxylase, or DOPD, is also implicated to play a role in positive 
regulation of inflammatory activity. In one study, it was found that recombinant DOPD binds 
CD74 with high affinity, leading to activation of ERK1/2 MAP kinase and downstream pro-
inflammatory pathways. DOPD also exhibits positive regulation of TNFα, IFNγ, and IL-1β 
production as well as immunoneutralization of DOPD was found to significantly reduce 
levels of these inflammatory chemicals (Merk et al, 2011).  
Pathogenesis of rheumatoid arthritis involves multiple cells, including macrophage, 
T- and B cells, angiogenic, osteoclasts and synoviocytes. The multiplicity of cell types 
requires complex signaling activity and molecules, possibly including S10A6, IPRI and 
22 
MCTPI, as revealed by the present study. For instance, IPRI and MCTP1 are involved in the 
release and modulation of calcium, which modulates multiple cellular responses, such as 
exocytosis, motility, proliferation and gene expression (Van Rossum et al, 2006; Shin et al, 
2005). S10A6 also plays a role in normal cell proliferation and is also localized in a variety 
of cancer phenotypes (Breen et al, 2003) and enhances pro-survival pathways in cancer. If 
these molecules induce similar proliferative effects in arthritic synoviocytes, they likely 
participate in promoting one of the hallmarks of RA progression (Emberley et al, 2004).  
This aberrant proliferation observed in the current study in arthritic cells could be 
closely linked to an increase in translation, which likely “fuels” or supports proliferation. 
Indeed, this may also likely explain the increase in the expression of proteins, such as 
LPPRC, discussed earlier. Interestingly, MO was able to not only block the expression of 
proliferation-promoting molecules, such as LPPRC and the aberrant cellular proliferation, but 
also inhibited expression of translation-associated proteins, implying that MO may repair 
dysregulation of cell proliferation in arthritic synoviocytes. Specifically, the proteins 
associated with translation that were downregulated by MO include IF4G1, involved in 
mRNA recruitment; WBP11, involved in mRNA processing, and RS4X, which is involved in 
ribosomal function (Gladyshev et al, 2010; Holcik & Sonenberg, 2005; Sudol et al, 2001; 
Watanabe et al, 1993). Decreased expression of IF4G1 may also have implications in the 
proliferative and apoptotic nature of the arthritic cells. Increased expression of IF4G1, which 
is common in breast cancers, was found to increase translation of mRNAs involved in cell 
survival, preventing autophagy and apoptosis. Reduced expression of the gene had the 
inverse effect (Badura et al, 2012). Therefore, the reduction in the expression of this gene in 
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the synoviocytes as a result of treatment with MO may reduce the overall proliferative 
activity of the cells. 
Proteins that are involved in protection and resistance to oxidative stress were found 
to be downregulated as a result of MO treatment of the arthritic cells. We deduce from these 
findings that the HFLS-RA cells may be upregulating these proteins in order to protect 
themselves from an environment high in ROSs to which they are exposed as exposure to 
these molecules can induce apoptosis (Hitchon & El-Gabalawy, 2004). While MO is known 
to be an antioxidant, we believe that MO likely acts upon the arthritic cells and makes them 
less resistant to oxidative stress by inhibiting the expression of the antioxidant proteins. This, 
in turn, would make them more susceptible to their hypoxic environment and thus may 
initiate apoptosis in the cells (Aruselvan et al., 2016; Hitchon & El-Gabalawy, 2004).  
Other than proliferation, arthritic cells also undergo changes in their shape and 
mobility (Kollias & Gkretsi, 2007). These two changes require cytoskeletal elements and 
possibly adhesion molecules (Janmey, 1998). For example, expression of MICA2, which has 
been implicated in cytoskeleton remodeling in metastatic cancer progression, cell-cell and 
cell-substrate adhesion, motility and invasion, was up regulated in arthritic cells, and has 
been previously reported to be down regulated by MO, consistent with the present data 
(Mariotti et al, 2016; Fremont et al, 2017). It has also been demonstrated in previous studies 
that depletion of MICAL1 (the family of molecules to which MICA2 belongs) reduced cell 
migration and invasion as well as ROS generation in breast cancer cells (Deng et al, 2016). 
Similarly to MICA2, CO6A3 is upregulated in cancer cells, specifically ovarian cancer cells. 
This protein is involved in both cell adhesion and cytoskeleton remodeling (Sherman-Baust 
et al, 2003). Staining of ovarian tumors with collagen VI antibodies confirmed its expression 
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in vivo and suggested reorganization of the extracellular matrix around the tumor. Also, the 
presence of CO6A3 was found to correlate with tumor grade, an ovarian cancer prognostic 
factor, suggesting that tumor cells may directly remodel their microenvironment to increase 
their survival in the presence of chemotherapeutic drugs, as higher expression of CO6A3 was 
found in ovarian cells resistant to chemotherapeutic treatment. (Sherman-Baust et al, 2003). 
In addition to reducing the expression of certain potentially clinically relevant 
proteins in the pathogenesis of RA, MO was also found to upregulate certain proteins. The 
functions of these proteins fell into one of three categories: apoptosis, stress resistance, and 
protection from inflammation. The pro-apoptotic gene of PDC61, encodes for a protein that 
binds to the products of the PDCD6 gene, which is involved in the apoptosis pathway 
(Hashemi et al 2015). Increase in its expression would correlate to an increase in apoptotic 
pathways. Kallistatin is responsible for conferring an anti-inflammatory response, as well as 
possessing anti-angiogenic properties and inhibiting tumor growth (Miao et al, 2002).  
HSP71 is also a protective protein in that it protects the proteasome from environmental 
stressors, such as inflammation. All the three proteins upregulated here have therapeutic 
implications in arthritis, i.e., protecting the cell from inflammatory and oxidative stressors is 
important as RA is a highly inflammatory condition with notable increases in the production 
of ROSs. If MO is able to restore cellular regulation of apoptosis while also protecting the 
cells of the joint from the unfavorable environment in the joint created by arthritis, then it can 
be deduced that MO would be a potential therapy in targeting the symptoms of arthritis and 
hampering disease progression. 
The limitations of the present study are many and include the following: 1). Since the 
development and progression of RA involves an intricate interplay of many cell types, 
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including immune cells, synoviocytes, blood vessel cells and their associated cytokines and 
chemokines, an in vivo model is more ideal; 2) Secondly, this study utilized the whole leaf 
ethanolic extract of MO. It would have been more beneficial if the subfractions and active 
compounds within the extract could have been identified so that the subfractions responsible 
for the observed desired effects could be isolated for further experimentation. 3) Lastly, it 
would have been more useful if a reference drug was used to which MO could have been 
compared in terms of efficacy. Future studies could utilize a widely used drug, such as 
methotrexate in order to determine how MO measures up to pharmaceuticals and whether it 
would be a suitable substitute in a clinical setting.   
We conclude that MO mitigates the expression of proteins implicated in the 
pathogenesis and progression of arthritis, notably inflammation, proliferation and oxidative 
stress, whereas on the other hand it (MO) enhances expression of proteins with potentially 
protective activities, such as apoptosis and anti-inflammation. These findings show that MO 
is a strong or potential candidate as an alternative therapy for RA. 
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Figures 
 
Figure 1. Data from MTT Assay shows that Moringa oleifera is not toxic to both healthy and 
arthritic cells. Healthy and arthritic cells were treated with varying concentrations (up to 75 
mg/mL) of MO for 24 hours. Cell viability was not affected in both arthritic and healthy cells 
below the concentration of 75 mg/mL.  
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Figure 2.  Heat map of the proteomic analysis shows Moringa oleifera’s effects on protein 
expression in human arthritic synoviocytes (HFLS-RA). Moringa oleifera reverses the 
aberrant expression of almost all the proteins in human fibroblast-like synoviocytes (HFLS-
RA), by down regulated most of their expression but up regulated a few of them. 
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A. 
 
B. 
 
Figure 3. Pie charts show that Moringa oleifera modulates protein expression in a cell model 
of arthritis. Moringa oleifera alters protein expression in biological processes such as: (A) 
translation, cell adhesion, cell signaling, inflammation and glycolysis by down regulation; 
(B) stress resistance, apoptosis, and anti-inflammation by enhancement.  
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Figure 4. Proteomics analysis shows that Moringa oleifera down regulates expression of cell 
adhesion-associated proteins in human arthritic synoviocytes (HFLS-RA). The two proteins 
are: (A). Collagen alpha-3(VI) chain (CO6A3) and (B) Thy-1 membrane glycoprotein 
(THY1). 
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Figure 5. Proteomics analysis shows that Moringa oleifera down regulates expression of 
translation-associated proteins in human arthritic synoviocytes (HFLS-RA). These proteins 
include: (A) UDP-glucose: glycoprotein glucosyltransferase 1 (UGG1), (B) WW domain-
binding protein 11 (WBP11), (C) Eukaryotic translation initiation factor 4 gamma 1 (IF4G1), 
(D) 40S ribosomal protein S4, X isoform (RS4X), (E) Vesicle-fusing ATPase (NSF), (F) 
Importin-5 (IPO5), (G) Importin-4 (IPO4), (H) Lysosomal protective protein (PPGB).  
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Figure 6. Proteomics analysis shows that Moringa oleifera down regulates expression of 
oxidative stress resistance-associated proteins in human arthritic synoviocytes (HFLS-RA). 
The three proteins include: (A) Serum para-oxonase/arylesterase 2 (PON2), (B) 
Peroxiredoxin-6 (PRDX6), (C) Superoxide dismutase (SODC). 
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Figure 7. Proteomics analysis shows that Moringa oleifera down regulates expression of cell 
signaling-associated proteins in human arthritic synoviocytes (HFLS-RA). The six proteins 
include: (A) Protein S100 A6 (S10A6), (B) Multiple C2 and transmembrane domain-
containing protein 1 (MCTP1), (C) Inositol 1,4,5-trisphosphate receptor-interacting 
protein (IPRI), (D) Protein AHNAK2 (AHNK), (E) Thy-1 membrane glycoprotein (THY1), 
(F) A-kinase anchor protein 12 (AKA12). 
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Figure 8. Proteomics analysis shows that Moringa oleifera down regulates expression of 
cytoskeleton-associated proteins in human arthritic synoviocytes (HFLS-RA). Two proteins – 
Spectrin beta chain, non-erythrocytic 1 (SPTB2), Protein-methionine sulfoxide oxidase 
MICAL2 (MICA2) – were found to be elevated in the proteome of the untreated arthritic 
cells. 
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Figure 9. Proteomics analysis shows that Moringa oleifera down regulates expression of 
inflammation-associated proteins in human arthritic synoviocytes (HFLS-RA). The three 
proteins include: (A) NEDD8, (B) Leucine-rich PPR motif-containing protein, 
mitochondrial (LPPRC) and (C) D-dopachrome decarboxylase.    
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Figure 10. Proteomics analysis shows that Moringa oleifera overall down regulates 
expression of proteins with cyto-protective roles in human arthritic synoviocytes (HFLS-
RA). These proteins include: (A) Heat shock 70 kDa protein 1A/1B (HSP71), (B) Kallistatin 
(KAIN), (C) Programmed cell death 6-interacting protein (PDC61), (D) Hemoglobin subunit 
alpha (HBA) and (E) Aldo-keto reductase family 1 member C1 (AK1C1). 
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Figure 11. Confocal images show that Moringa oleifera down regulates the expression of 
NF-ƙB in human fibroblast-like synoviocytes (HFLS-RA) (A) compared to (B) vehicle. 
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